pertibrutinib

JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says
Fierce Pharma
Thu, 01/12/23 - 10:27 am
JPMHC 2023
Eli Lilly
pertibrutinib
donanemab
mirikizumab
lebrikizumab